Influenza virus replicated in mammalian cell culture and vaccine production
US5824536A · kind A · utility
25Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 1996 |
| Grant date | Oct 20, 1998 |
| Priority date | — |
| Expiry date | Jun 17, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16152
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides replication of high growth influenza virus strains, derived from clinical isolates, in cultured mammalian cells by infecting the mammalian cells with the high growth strains to obtain infected cells, and culturing the cells while maintaining a trypsin concentration range of 0.05-1.0 .mu.g/ml in the culture medium, where the resulting replicated virus is suitable for use in mammalian influenza vaccines and vaccination methods, which are also provided by the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.